AngioDynamics (NASDAQ:ANGO) Issues FY25 Earnings Guidance

AngioDynamics (NASDAQ:ANGO) issued an update on its FY25 earnings guidance on Wednesday morning. The company provided earnings per share guidance of ($0.34)-($0.31) for the period, compared to the consensus earnings per share estimate of ($0.37). The company issued revenue guidance of $285-288 million, compared to the consensus revenue estimate of $284.89 million. AngioDynamics also updated its FY 2025 guidance to -0.340–0.310 EPS.

Analyst Ratings Changes

Separately, HC Wainwright increased their price target on AngioDynamics from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Friday, January 10th.

AngioDynamics Stock Up 12.4 %

NASDAQ ANGO opened at $10.86 on Thursday. AngioDynamics has a 52 week low of $5.47 and a 52 week high of $13.50. The firm has a 50 day moving average of $10.28 and a two-hundred day moving average of $8.85. The stock has a market capitalization of $439.46 million, a PE ratio of -1.93 and a beta of 0.56.

AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Wednesday, April 2nd. The medical instruments supplier reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.16. The firm had revenue of $72.00 million during the quarter, compared to the consensus estimate of $70.30 million. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The company’s revenue was down 4.3% on a year-over-year basis. On average, equities research analysts expect that AngioDynamics will post -0.37 earnings per share for the current fiscal year.

Insider Activity

In related news, SVP Warren Nighan, Jr. sold 4,060 shares of the firm’s stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $12.31, for a total transaction of $49,978.60. Following the transaction, the senior vice president now owns 41,817 shares in the company, valued at $514,767.27. This trade represents a 8.85 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 5.40% of the company’s stock.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.